NPM1 and acute myeloid leukemia: Even if the precision of ddPCR assay, combined with its broad applicability also in patients ineligible for RQ-PCR MRD assessment, should be recognized, it should also be noted that RQ-PCR actually still performs more than adequately for MRD detection in most NPM1-mutated AML patients, is less expensive, and many clinical laboratories already possess the equipment and technical expertise for this molecular analysis [98].